Skip to Main Content

Paper Details

mTOR inhibition overcomes RSK3-mediated resistance to BET inhibitors in small cell lung cancer.
JCI Insight
6
2023
AKT, BAD, BET, BETis, PI-3K, RSK3, SCLC, SCLC models, Small cell lung cancer, TSC2, mTOR, mTORis, malignancy, p70S6K1, patients, small cell lung cancer, tumor, xenograft models
Author NameAffiliation
Xiaohu ZhangDivision of Preclinical Innovation, National Center for Advancing Translational Sciences
Michele CeribelliDivision of Preclinical Innovation, National Center for Advancing Translational Sciences
Craig J ThomasDivision of Preclinical Innovation, National Center for Advancing Translational Sciences
Craig J ThomasCenter for Cancer Research, National Cancer Institute
Beverly A MockCenter for Cancer Research, National Cancer Institute
David S Schrump
David S Schrump
  • 1 - 7

Datasets

Release 1.2